GLP-1s after pregnancy: separating postpartum weight loss facts from TikTok hype

What did @inisaya5338 actually say?

Honestly, this one is a challenge to fact-check. The transcript consists entirely of words that appear to be in a language other than English: "Salah, Sankha, Yandim, Rum Chana Ka, Gavodha, Adha, Sathua." These terms do not correspond to any recognized medical terminology, GLP-1 drug names, or commonly documented phrases in the semaglutide conversation space. Without a translation, there is no verifiable medical claim to assess on its face.

The hashtags tell us more than the words do. The creator tagged this #OzempicJourney, #BackToMyself, and #PostpartumRealness, which strongly suggests this is a personal account of using semaglutide (the active ingredient in Ozempic and Wegovy) during or after the postpartum period. That context matters clinically, and it matters a lot.

Does the science back this up?

We cannot evaluate the spoken claims without a translation, so we cannot confirm or deny them with studies. What we can do is address the implied context: postpartum GLP-1 use. The evidence here is genuinely thin, and that should give anyone pause.

Semaglutide has not been studied in large postpartum trials. The pivotal STEP trials (Wilding et al., 2021, New England Journal of Medicine) excluded pregnant and breastfeeding individuals entirely. Current prescribing guidelines from the FDA label semaglutide as a category where the drug should be discontinued at least two months before a planned pregnancy, and its safety during breastfeeding has not been established in human studies. A 2023 review in Obstetrics and Gynecology by Donoghue and colleagues noted the absence of controlled data on GLP-1 receptor agonists in the postpartum window and called for prospective studies. Sharing an Ozempic journey without flagging these gaps is, at minimum, an incomplete picture for a postpartum audience.

What did they get wrong (or right)?

We cannot fairly say the creator stated something medically wrong, because the spoken content is not translatable from the available transcript. Attributing error to someone based on sounds we cannot understand would itself be inaccurate, and that is not how responsible fact-checking works.

What we can flag is a structural problem: posting GLP-1 content aimed at a postpartum audience without clear disclosures carries real risk regardless of language. Postpartum individuals watching this video, drawn in by the hashtags, may interpret the creator's apparent positive experience as an endorsement of semaglutide use during breastfeeding or early postpartum recovery. That inference could be harmful. The creator may have done everything right in the audio, but the framing creates a gap. TikTok's algorithm does not distinguish between responsible personal testimony and implicit medical advice, and neither do vulnerable new parents scrolling at 2 a.m.

What should you actually know?

If you are postpartum and considering a GLP-1 medication, several things are worth knowing before you act on any social media content, including this video.

• Semaglutide (Ozempic, Wegovy) is not approved for postpartum weight loss specifically. Its approvals are for type 2 diabetes management and chronic weight management in adults meeting specific BMI criteria.
• Breastfeeding safety is unknown. Animal studies have shown semaglutide passes into milk, but human lactation data does not exist in sufficient quantity to draw conclusions (FDA label, 2023).
• Postpartum weight retention has its own clinical trajectory. Most guidelines, including those from the American College of Obstetricians and Gynecologists, recommend a minimum of six weeks postpartum before initiating structured weight loss interventions, and GLP-1 agents fall outside standard postpartum protocols entirely.
• Personal testimonials on social media, even genuine and well-meaning ones, cannot substitute for a conversation with a licensed provider who knows your full history.

If you are curious whether a GLP-1 medication is appropriate for your situation, a regulated telehealth platform with licensed clinicians is the right place to start that conversation, not a TikTok comments section.